Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 ...
Let me start, I’d like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may ...
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we ...
TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as ...
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price target is Yen4,500.00. Miki Sogi’s rating is based ...
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing ...
We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...
Investing.com-- Bank of America (BofA) analysts highlighted several Japanese stocks as top picks following strong ...
According to Insider Monkey’s Q3 database, 12 hedge funds were bullish on Takeda Pharmaceutical Company Limited (NYSE:TAK), an increase from 10 funds in the last quarter. Israel Englander’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback